Noxopharm reports Covid-19 trial programme to commence in Europe

This article was originally published here

This action is designed to provide important safety data and proof-of-principle of using Veyonda, a drug that blocks cGAS-STING signaling, as a potential treatment of the cytokine storm

The post Noxopharm reports Covid-19 trial programme to commence in Europe appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply